Free Trial
OTCMKTS:PBSV

Pharma-Bio Serv (PBSV) Stock Price, News & Analysis

Pharma-Bio Serv logo
$0.50 +0.08 (+17.65%)
As of 05/9/2025 11:12 AM Eastern

About Pharma-Bio Serv Stock (OTCMKTS:PBSV)

Key Stats

Today's Range
$0.50
$0.50
50-Day Range
$0.40
$0.55
52-Week Range
$0.31
$0.75
Volume
3,600 shs
Average Volume
9,207 shs
Market Capitalization
$11.47 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Pharma-Bio Serv, Inc. operates as a compliance and technology transfer services consulting firm in Puerto Rico, the United States, Europe, Brazil, and internationally. The company provides technical compliance consulting services comprising regulatory compliance, validation, technology transfer, engineering, project management, and process support for the pharmaceutical, chemical manufacturing, biotechnology, medical device, cosmetic, food industries, and allied products companies. Pharma-Bio Serv, Inc. was founded in 1993 and is headquartered in Dorado, Puerto Rico.

Receive PBSV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pharma-Bio Serv and its competitors with MarketBeat's FREE daily newsletter.

PBSV Stock News Headlines

PBSV Returns to Growth
Musk’s Project Colossus could mint millionaires
I predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new millionaires than any tech advance in history. And for a limited time, you have the chance to claim a stake in this project, even though it’s housed inside Elon’s private company, xAI.
PBSV Makes Progress on Improvements
See More Headlines

PBSV Stock Analysis - Frequently Asked Questions

Pharma-Bio Serv's stock was trading at $0.5499 on January 1st, 2025. Since then, PBSV stock has decreased by 9.1% and is now trading at $0.50.
View the best growth stocks for 2025 here
.

Pharma-Bio Serv, Inc. (OTCMKTS:PBSV) issued its quarterly earnings data on Monday, March, 17th. The company reported $0.37 EPS for the quarter, topping analysts' consensus estimates of $0.02 by $0.35. The company earned $2.47 million during the quarter, compared to analysts' expectations of $2.70 million. Pharma-Bio Serv had a negative trailing twelve-month return on equity of 5.61% and a negative net margin of 8.18%.

Shares of PBSV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Pharma-Bio Serv investors own include AT&T (T), Annaly Capital Management (NLY), BlackRock Multi-Sector Income Trust (BIT), GE Aerospace (GE), Exxon Mobil (XOM), Enterprise Products Partners (EPD) and First BanCorp. (FBP).

Company Calendar

Record date for 3/20 Dividend
2/28/2025
Ex-Dividend for 3/20 Dividend
2/28/2025
Last Earnings
3/17/2025
Dividend Payable
3/20/2025
Today
5/12/2025
Next Earnings (Estimated)
6/13/2025
Fiscal Year End
10/31/2025

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Industry
Management consulting services
Sub-Industry
Business Services
Current Symbol
OTCMKTS:PBSV
Employees
185
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
4.55
P/E Growth
N/A
Net Income
$-780,000.00
Pretax Margin
-7.94%

Debt

Sales & Book Value

Annual Sales
$9.51 million
Price / Cash Flow
N/A
Book Value
$0.60 per share
Price / Book
0.83

Miscellaneous

Free Float
20,162,000
Market Cap
$11.47 million
Optionable
Not Optionable
Beta
0.64

Social Links

2025 Gold Forecast: A Perfect Storm for Demand Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

This page (OTCMKTS:PBSV) was last updated on 5/13/2025 by MarketBeat.com Staff
From Our Partners